Cellnex


A solid 7% organic growth at the high end of the group's objectives

29/04/24 -"After the slowdown in the Q4 Cellnex released reassuring Q1 figures with 7% organic revenue and EBITDA growth. To secure an investment grade rating the group announced in March the sale of its Irish ..."

Pages
59
Language
English
Published on
29/04/24
You may also be interested by these reports :
17/05/24
The Q1 numbers released on 14 May were fairly decent with a strong growth in revenues (+9%) and an EBITDA up by 2% yoy. OTE’s FCF is expected to be ...

16/05/24
We have adjusted our model by excluding the Spanish and Italian operations from Vodafone’s accounts (following the announcement of the sale ...

16/05/24
The Q1 met expectations and was satisfactory. Capex decreased by 2% to €4.7bn. In the US, capex dropped by 15% to €2.4bn, thanks to the rapid ...

16/05/24
The Q4 missed our expectations, with flat revenues and an EBITDA down by 3%. However, given that Capex declined by 3.5%, the dividend will be up by ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO